candesartan has been researched along with Hormone-Dependent Neoplasms in 2 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takahashi, S | 1 |
| Uemura, H | 2 |
| Seeni, A | 1 |
| Tang, M | 1 |
| Komiya, M | 1 |
| Long, N | 1 |
| Ishiguro, H | 2 |
| Kubota, Y | 2 |
| Shirai, T | 1 |
| Ikeda, N | 1 |
| Nakaigawa, N | 1 |
| Ouchi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer[NCT06168487] | Early Phase 1 | 42 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for candesartan and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
[A novel molecular target therapeutics for refractory prostate cancer].
Topics: Alitretinoin; Androgens; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compoun | 2002 |
1 other study available for candesartan and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Benzoates; Biphenyl Com | 2012 |